What is Karius?
Founded in 2014 and headquartered in Redwood City, California, Karius is dedicated to providing genomic insights for infectious diseases. Its technology enables clinicians to make life-saving treatment decisions by rapidly identifying pathogens responsible for serious infections. The company's approach leverages advanced genomics to offer a comprehensive view of the microbial landscape, aiming to improve patient outcomes and streamline diagnostic workflows in a critical area of healthcare.
Karius operates within the rapidly evolving field of molecular diagnostics, a sector experiencing substantial investment due to the increasing demand for accurate and timely disease identification. The company's focus on infectious diseases positions it to address a significant global health challenge.
How much funding has Karius raised?
Karius has raised a total of $320M across 4 funding rounds:
Other Financing Round
$5M
Series A
$50M
Unspecified
$165M
Series C
$100M
Other Financing Round (2014): $5M with participation from Lightspeed Venture Partners, Data Collective, and Innovation Endeavors
Series A (2017): $50M led by Data Collective, Innovation Endeavors, Pacific 8 Ventures, Lightspeed Venture Partners, and Tencent
Unspecified (2020): $165M supported by HBM Healthcare Investments, Khosla Ventures, SoftBank Vision Fund 21, LightSpeed Venture Partners, and General Catalyst
Series C (2024): $100M featuring Gilde Healthcare, 5AM Ventures, General Catalyst, Khosla Ventures, HBM Healthcare Investments, and Seventure Partners
Key Investors in Karius
Gilde Healthcare
Gilde Healthcare is a specialized healthcare investment firm managing over €1.4 billion across various fund strategies, focusing on businesses that enable better care at lower costs. They invest in healthtech, therapeutics, and climate-related companies.
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies and help bring new therapies to patients.
General Catalyst
General Catalyst is a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors and stages, backing entrepreneurs and management teams pursuing ambitious visions that reshape their respective industries.
What's next for Karius?
With the recent infusion of major strategic capital, Karius is poised for accelerated expansion and further development of its diagnostic platform. This enterprise-level funding is expected to fuel advancements in its genomic sequencing technology, enhance its commercial reach, and potentially broaden its application to other complex diseases.
The company's trajectory suggests a move towards wider clinical adoption and integration into standard healthcare practices. Future strategic initiatives may include partnerships with healthcare systems, further research into novel infectious agents, and the scaling of its operational capacity to meet growing market demand. The sustained investment indicates strong confidence in Karius's mission to transform infectious disease diagnostics.
